Sustained virologic response rates for hepatitis C virus are difficult to achieve in patients infected with human immunodeficiency virus, especially if they have other poor predictors of response. Rates of sustained virologic response for hepatitis C virus genotype 1 in patients with end stage kidney disease are lower than patients with normal renal function. We present the first case report of a co-infected African American man with end stage kidney disease, who was haemodialysis dependant, and an interferon non-responder with advanced liver fibrosis, who achieved sustained virologic response on a telaprevir-based regimen.
ShermanKERousterSDChungRT. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis2002; 34: 831–837.
2.
BerenguerJAlvarez-PellicerJMartinP. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. Hepatology2009; 50: 407–413.
3.
Rodriguez-TorresMSlimJBhattiL. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials2012; 13: 142–152.
4.
SulkowskiMSShermanKEDieterichDT. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 Infection in patients with HIV: a randomized trial. Ann Intern Med2013; 159: 86–96.
5.
SulkowskiMPolSMallolasJ. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis2013; 13: 597–605.
6.
KnollGATankersleyMRLeeJY. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis1997; 29: 608–614.
7.
WeberRSabinCFriis-MøllerN. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med2006; 166: 1632–1641.
8.
MacíasJMárquezMTéllezF. Risk of liver decompensations among human immunodeficiency virus/hepatitis c virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis2013; 57: 1401–1408.
9.
LacombeKValinNStitouH. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results. AIDS2013; 27: 1356–1359.
10.
CachayERWylesDLTorrianiFJ. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. AIDS2013; 27: 2893–2897.
11.
SedenKBackDKhooS. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother2010; 65: 1079–1085.
12.
SeeligRRenzMBottnerC. Hepatitis C virus infections in dialysis units: prevalence of RNA and antibodies to HCV. Ann Med1994; 26: 45–52.
13.
FabriziFTakkoucheBLunghiG. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat2007; 14: 697–703.
14.
GhanyMGStraderDBThomasDL. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009; 49: 1335–1374.
15.
GlueP. The clinical pharmacology of ribavirin. Semin Liver Dis1999; 19: 17–24.
16.
MarcellinPFornsXGoeserT. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology2011; 140: 459–468.
